Sign inJoin waitlistJoin the waitlist

Jacob Orme

Assistant Professor of Oncology · Mayo Clinic College of Medicine and Science

Credentials: · · · · ·

History

Mayo Clinic College of Medicine and Science
Present
Mayo Clinic College of Medicine and Science
Present

Hematology and Medical Oncology
Mayo Clinic College of Medicine and Science
2019–2022
Internal Medicine
Mayo Clinic College of Medicine and Science
2016–2019
Univ of Texas Southwestern Med Sch at Dallas
2012–2016

Research

ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance
OncoImmunology · 2020 · First of 16 authors · Corresponding · 108 citations
A noncanonical AR addiction drives enzalutamide resistance in prostate cancer
Nature Communications · 2021 · 87 citations
Theranostics and artificial intelligence: new frontiers in personalized medicine
Review · Theranostics · 2024 · 78 citations

Daniel Childs
42 papers · 2 as a fellow
Oliver Sartor
21 papers
Eugene Kwon
20 papers
Geoffrey Johnson
20 papers
Sean Park
19 papers
Irbaz Riaz
17 papers · 17 as a fellow
Ayse Kendi
13 papers
Jack Andrews
13 papers · 13 as a resident
Lance Pagliaro
12 papers
Brian Costello
11 papers
Haidong Dong
10 papers
Matt Thorpe
10 papers

Grants

Exploiting SPOP for Novel Synthetic Lethality Mechanisms in Prostate Cancer
National Cancer Institute · K08
Contact PI · $307.4K · Mayo Clinic Rochester
2026–2031
Overcoming Immune Checkpoint Inhibition with Therapeutic Plasma Exchange and Radiotherapy in Melanoma
National Cancer Institute · R21
PI · $363.3K · Mayo Clinic Rochester
2021–2024

Clinical trials

Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers
Principal investigator · Recruiting · Phase 2
Mayo Clinic
2025–2028
Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial
Principal investigator · Recruiting · Phase 4
Mayo Clinic
2025–2034
Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial
Principal investigator · Recruiting · Phase 2
Mayo Clinic
2024–2031
Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer
Principal investigator · Completed · Phase 2
Mayo Clinic
2024–2025